LPL Financial
SPRY icon

LPL Financial’s ARS Pharmaceuticals SPRY Stock Holding History

LPL Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
26,184
+1,000
+4% +$8.6K ﹤0.01% 5725
2026
Q1 		$202K Buy
25,184
+2,268
+10% +$21.7K ﹤0.01% 5490
2025
Q4 		$267K Sell
22,916
-168
-0.7% -$1.63K ﹤0.01% 5237
2025
Q3 		$232K Sell
23,084
-2,817
-11% -$40.4K ﹤0.01% 5245
2025
Q2 		$452K Buy
25,901
+908
+4% +$13.1K ﹤0.01% 4458
2025
Q1 		$314K Buy
24,993
+3,585
+17% +$43.1K ﹤0.01% 4540
2024
Q4 		$226K Buy
21,408
+2,190
+11% +$30.7K ﹤0.01% 4741
2024
Q3 		$279K Buy
19,218
+9,039
+89% +$108K ﹤0.01% 4494
2024
Q2 		$86.6K Buy
+10,179
New +$90.3K ﹤0.01% 4764

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LPL Financial's SPRY Position: Q2 2026 in Review

LPL Financial increased its ARS Pharmaceuticals (SPRY) stake by 4% in Q2 2026, buying an estimated $8.6K and bringing the position to 26,184 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #5725.

LPL Financial first reported a position in SPRY in Q2 2024 and has held it in 9 quarters since. The position peaked at $452K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • LPL Financial held 26,184 shares of ARS Pharmaceuticals worth $210K as of Q2 2026.
  • LPL Financial bought 1,000 ARS Pharmaceuticals shares in Q2 2026, an estimated $8.6K.
  • ARS Pharmaceuticals made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5725 holding.
  • LPL Financial first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • LPL Financial's ARS Pharmaceuticals position peaked at $452K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.